175 related articles for article (PubMed ID: 9656778)
1. [Cellular immunotherapy in chronic myeloid leukemia].
Fernández MN
Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
[No Abstract] [Full Text] [Related]
2. [Interferon alpha in the treatment of chronic myeloid leukemia. Promises, realities, and perspectives].
Steegmann JL; Granados E; Rodríguez-Salvanés F; Casado LF; Giraldo P; Lavilla E; Gómez-Casares MT; Fernández-Contreras E; Odriozola J
Sangre (Barc); 1998 Apr; 43(2):137-46. PubMed ID: 9656775
[No Abstract] [Full Text] [Related]
3. Adoptive immunotherapy following allogeneic bone marrow transplantation.
Dazzi F; Goldman JM
Annu Rev Med; 1998; 49():329-40. PubMed ID: 9509267
[TBL] [Abstract][Full Text] [Related]
4. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia.
Ruiz-Argüelles GJ; Gómez-Almaguer D; López-Martínez B; Cantú-Rodríguez OG; Jaime-Pérez JC; González-Llano O
Haematologica; 2002 Aug; 87(8):894-6. PubMed ID: 12161373
[No Abstract] [Full Text] [Related]
5. Graft-versus-leukemia reactions following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S
Prog Clin Biol Res; 1992; 377():113-25; discussion 126-7. PubMed ID: 1438407
[No Abstract] [Full Text] [Related]
6. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
8. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué C; Grañena A
Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
[No Abstract] [Full Text] [Related]
9. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
[TBL] [Abstract][Full Text] [Related]
10. The management of chronic myeloid leukaemia--a case history.
Sureda A; Hernández-Bronchud M
Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713
[No Abstract] [Full Text] [Related]
11. Adoptive immunotherapy in human and canine chimeras--the role of interferon alfa. EBMT Chronic Leukemia Working Party.
Kolb HJ; Mittermüller J; Hertenstein H; Schumm M; Holler E; de Witte T; Günther W; Ljungman P; Goldman JM
Semin Hematol; 1993 Jul; 30(3 Suppl 3):37-9. PubMed ID: 8235705
[No Abstract] [Full Text] [Related]
12. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
13. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
Owaidah TM
Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
[TBL] [Abstract][Full Text] [Related]
14. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
[TBL] [Abstract][Full Text] [Related]
15. [Donor leukocyte transfusion in a patient with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation: analysis of natural killer cell activity and T-cell receptor repertoire in bone marrow T cells that exhibited graft-versus-leukemia activity].
Suehiro Y; Muta K; Umemura T; Motomura S; Nishimura J; Nawata H; Kimura N
Rinsho Ketsueki; 1999 Jan; 40(1):40-5. PubMed ID: 10067095
[TBL] [Abstract][Full Text] [Related]
16. Management of late CML relapse.
Flowers M
Biol Blood Marrow Transplant; 2008 Jul; 14(7):847-8. PubMed ID: 18541206
[No Abstract] [Full Text] [Related]
17. Prophylactic use of interferon alfa after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT.
Niederwieser D; Arcese W; Bandini G; Schwaighofer H; Thaler J; Bosi A; Di Bartolomeo P; Alessandrino EP; Urban C; Gratwohl A
Semin Hematol; 1993 Jul; 30(3 Suppl 3):40-3. PubMed ID: 8235706
[No Abstract] [Full Text] [Related]
18. Chronic myeloid leukemia.
Sawyers CL
N Engl J Med; 1999 Apr; 340(17):1330-40. PubMed ID: 10219069
[No Abstract] [Full Text] [Related]
19. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
20. Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia.
Au WY; Chan AC; Lie AK; So JC; Liang R; Kwong YL
Bone Marrow Transplant; 1998 Jul; 22(1):99-102. PubMed ID: 9678803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
